These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15046713)

  • 1. Novel clinical trials in androgen-independent prostate cancer.
    Gulley J; Dahut W
    Clin Prostate Cancer; 2002 Jun; 1(1):51-7. PubMed ID: 15046713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What's new in the treatment of advanced prostate cancer?
    Sternberg CN
    Eur J Cancer; 2003 Jan; 39(2):136-46. PubMed ID: 12509944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target to apoptosis: a hopeful weapon for prostate cancer.
    Tang DG; Porter AT
    Prostate; 1997 Sep; 32(4):284-93. PubMed ID: 9288188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current chemotherapeutic approaches for androgen-independent prostate cancer.
    Rumohr JA; Chang SS
    Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for androgen-independent prostate cancer.
    Gulley J; Figg WD; Dahut WL
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):49-57. PubMed ID: 16227960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
    Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
    Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
    Figg WD
    Clin Pharmacol Ther; 2006 Jan; 79(1):1-8. PubMed ID: 16413236
    [No Abstract]   [Full Text] [Related]  

  • 9. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
    Lim JT; Piazza GA; Han EK; Delohery TM; Li H; Finn TS; Buttyan R; Yamamoto H; Sperl GJ; Brendel K; Gross PH; Pamukcu R; Weinstein IB
    Biochem Pharmacol; 1999 Oct; 58(7):1097-107. PubMed ID: 10484067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
    Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):62-6. PubMed ID: 11685731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetastatic drugs in prostate cancer.
    Chay CH; Cooper CC; Hellerstedt BA; Pienta KJ
    Clin Prostate Cancer; 2002 Jun; 1(1):14-9. PubMed ID: 15046708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic approaches to advanced prostate cancer.
    Armstrong AJ; Carducci MA
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
    Gulley J; Dahut WL
    Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
    Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New targeted therapies in hormone-refractory prostate cancer].
    Oudard S; Banu E; Scotte F; Beuzeboc P; Guyader C; Medioni J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F62-8. PubMed ID: 17845995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer.
    Dawson NA; Slovin SF
    Urology; 2003 Dec; 62 Suppl 1():102-18. PubMed ID: 14747048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.